A S Wierzbicki

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Curr Med Res Opin 21:299-306. 2005
  2. doi Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Int J Clin Pract 62:701-7. 2008
  3. ncbi FIELDS of dreams, fields of tears: a perspective on the fibrate trials
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Int J Clin Pract 60:442-9. 2006
  4. ncbi Impaired renal function and atherosclerosis in a Pakistani cohort
    Anthony S Wierzbicki
    Department of Chemical Pathology St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Curr Med Res Opin 21:1201-7. 2005
  5. ncbi Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital Lambeth Palace Road, London SE1 7EH, UK
    Atherosclerosis 185:421-5. 2006
  6. doi New therapies to reduce low-density lipoprotein cholesterol
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, St Thomas Hospital Campus, London, UK
    Curr Opin Cardiol 28:452-7. 2013
  7. doi Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia
    Rosemary E J Clarke
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Heart 99:175-80. 2013
  8. doi Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, Lambeth Palace Road, London SE1 7EH, UK 0207 188 1256 0207 188 7325
    Expert Opin Biol Ther 13:7-10. 2013
  9. doi Nonalcoholic fatty liver disease and lipids
    Anthony S Wierzbicki
    Department of Metabolic Medicine Chemical Pathologyemical Pathology, Guy s and St Thomas Hospitals, London, UK
    Curr Opin Lipidol 23:345-52. 2012
  10. doi New directions in cardiovascular risk assessment: the role of secondary risk stratification markers
    A S Wierzbicki
    Consultant in Metabolic Medicine Chemical Pathology, St Thomas Hospital Campus, Lambeth Palace Road, London SE1 7EH, UK
    Int J Clin Pract 66:622-30. 2012

Detail Information

Publications115 found, 100 shown here

  1. ncbi Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Curr Med Res Opin 21:299-306. 2005
    ..The available clinical evidence suggests that addition of nicotinic acid to primary lipid-lowering therapy has an important atheroprotective role in patients with or at risk of developing CHD...
  2. doi Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Int J Clin Pract 62:701-7. 2008
    ..To determine the relationship between insulin resistance (IR) and atheroma burden in Pakistanis...
  3. ncbi FIELDS of dreams, fields of tears: a perspective on the fibrate trials
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Int J Clin Pract 60:442-9. 2006
    ..Fenofibrate is a reasonable second-line therapy for dyslipidaemia in diabetes and safe in combination therapy. Its benefits on microvascular disease and in combination therapy require further confirmation...
  4. ncbi Impaired renal function and atherosclerosis in a Pakistani cohort
    Anthony S Wierzbicki
    Department of Chemical Pathology St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Curr Med Res Opin 21:1201-7. 2005
    ..To investigate the relationship of creatinine and calculated glomerular filtration rate (GFR) with coronary arterial disease (CAD) in Pakistani patients...
  5. ncbi Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital Lambeth Palace Road, London SE1 7EH, UK
    Atherosclerosis 185:421-5. 2006
    ..Erectile dysfunction is related to penile arterial endothelial nitric oxide production. Asymmetric dimethylarginine (ADMA) and E-selectin are often considered plasma markers of endothelial function...
  6. doi New therapies to reduce low-density lipoprotein cholesterol
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, St Thomas Hospital Campus, London, UK
    Curr Opin Cardiol 28:452-7. 2013
    ..Statins currently form the standard of care but are not able to reduce low-density lipoprotein cholesterol (LDL-C) adequately in all patients - particularly those with familial hypercholesterolaemia and those with statin intolerance...
  7. doi Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia
    Rosemary E J Clarke
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Heart 99:175-80. 2013
    ..To determine the utility of secondary stratification measures to improve the ascertainment of index cases of familial hypercholesterolaemia (FH)...
  8. doi Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, Lambeth Palace Road, London SE1 7EH, UK 0207 188 1256 0207 188 7325
    Expert Opin Biol Ther 13:7-10. 2013
    ..Alipogene tiparvovec is the first possibly curative treatment for LPL deficiency...
  9. doi Nonalcoholic fatty liver disease and lipids
    Anthony S Wierzbicki
    Department of Metabolic Medicine Chemical Pathologyemical Pathology, Guy s and St Thomas Hospitals, London, UK
    Curr Opin Lipidol 23:345-52. 2012
    ..This article reviews the mechanisms leading to the development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) and the effects of hypoglycaemic and lipid-lowering therapies on NAFLD/NASH...
  10. doi New directions in cardiovascular risk assessment: the role of secondary risk stratification markers
    A S Wierzbicki
    Consultant in Metabolic Medicine Chemical Pathology, St Thomas Hospital Campus, Lambeth Palace Road, London SE1 7EH, UK
    Int J Clin Pract 66:622-30. 2012
    ..Large scale meta-analyses ideally of pooled primary patient data will be required to determine the best additional markers to add to conventional risk prediction and in what groups to apply them...
  11. doi Triglycerides: a case for treatment?
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, London, Lambeth, UK
    Curr Opin Cardiol 27:398-404. 2012
    ..To discuss the relevance of triglycerides to cardiovascular disease (CVD) risk...
  12. doi Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia
    Anthony S Wierzbicki
    St Thomas Hospital Campus, Department of Chemical Pathology, Lambeth Palace Road, London, UK
    Expert Opin Investig Drugs 21:667-76. 2012
    ..Autosomal dominant activating mutations in PCSK-9 cause familial hypercholesterolaemia whereas inactivating mutations in man reduce LDL cholesterol (LDL-C) and are associated with a decreased lifetime risk of cardiovascular events...
  13. doi Diagnosis and treatment of severe hypertriglyceridemia
    Adie Viljoen
    Lister Hospital, Stevenage, Hertfordshire, SG1 4AB, UK
    Expert Rev Cardiovasc Ther 10:505-14. 2012
    ....
  14. doi New lipid-lowering drugs: an update
    A S Wierzbicki
    Metabolic Medicine Chemical Pathology, St Thomas Hospital Campus, London, UK
    Int J Clin Pract 66:270-80. 2012
    ..Lipid-lowering drugs are likely to prove a fast-developing area for novel treatments as possible synergies exist between new and established compounds for the treatment of atherosclerosis...
  15. ncbi Rimonabant: endocannabinoid inhibition for the metabolic syndrome
    A S Wierzbicki
    Lipid Unit, St Thomas Hospital, London, UK
    Int J Clin Pract 60:1697-706. 2006
    ..Thus rimonabant has major effects on both the metabolic syndrome and cardiovascular risk factors thus has the potential to reduce the risks of type 2 diabetes and cardiovascular disease associated with the cardiometabolic phenotype...
  16. ncbi New lipid-lowering agents
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital Campus, Lambeth Palace Road, London, SE1 7EH, UK
    Expert Opin Emerg Drugs 8:365-76. 2003
    ..Lipid-lowering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis...
  17. ncbi Fibrates after the FIELD study: Some answers, more questions
    Anthony S Wierzbicki
    St Thomas Hospital, London, SE1 7EH, UK
    Diab Vasc Dis Res 3:166-71. 2006
    ....
  18. ncbi Lipid-altering therapies and the progression of atherosclerotic disease
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London, SE1 7EH, UK
    Cardiovasc Intervent Radiol 30:155-60. 2007
    ..It is likely that the management of significant carotid stenosis will become ever more drug focused and will be customized to the lipid profile of each patient with intervention reserved only for late-stage symptomatic disease...
  19. ncbi Interpreting clinical trials of diabetic dyslipidaemia: new insights
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Diabetes Obes Metab 11:261-70. 2009
    ..Results are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes trial to fully evaluate the outcome benefits of this combination strategy...
  20. ncbi Statin-fibrate combination: therapy for hyperlipidemia: a review
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Curr Med Res Opin 19:155-68. 2003
    ..In conclusion, fibrate + statin therapy remains an option in high-risk patents. However, long-term studies involving safety monitoring and vascular endpoints are required to demonstrate the efficacy of this regimen...
  21. ncbi Familial combined hyperlipidaemia: under - defined and under - diagnosed?
    Anthony S Wierzbicki
    St Thomas Hospital, London SE 1 7EH, UK
    Curr Vasc Pharmacol 6:13-22. 2008
    ....
  22. ncbi Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease
    Anthony S Wierzbicki
    Department of Chemical Pathology, Chelsea and Westminster Hospital, 369 Fulham Road, London, United Kingdom
    J Lipid Res 44:1481-8. 2003
    ..omega-Oxidation forms a functional reserve capacity that enables patients with ARD undergoing acute stress to cope with limited increases in plasma PA levels...
  23. ncbi Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, U K
    Biochem Soc Trans 35:881-6. 2007
    ....
  24. ncbi Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
    Int J Cardiol 128:77-82. 2008
    ..Metabolic syndrome (M-IRS) is common in Asians. This study investigated the relationship of two definitions of M-IRS to atherosclerosis in Indian Asians with suspected coronary arterial disease (CAD)...
  25. ncbi Lipid-altering agents: the future
    A S Wierzbicki
    St Thomas Hospital Campus, London, UK
    Int J Clin Pract 58:1063-72. 2004
    ..Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis...
  26. ncbi Lipid-lowering therapies in development
    Anthony S Wierzbicki
    St Thomas Hospital, Department of Chemical Pathology, Lambeth Palace Road, London, SE1 7EH, UK
    Expert Opin Investig Drugs 13:1405-18. 2004
    ..Any new drugs will also have to be assessed in clinical end-point trials against current compounds with proven outcome benefits...
  27. ncbi Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Curr Med Res Opin 21:333-8. 2005
    ..To investigate the efficacy of the cholesterol absorption inhibitor ezetimibe in patients with refractory familial hyperlipidaemia or intolerant to statin therapy...
  28. pmc Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas s Hospital, London SE1 7EH, UK
    Heart 91:1003-7. 2005
    ..To assess the relation of the metabolic insulin resistance syndrome (M-IRS) with coronary heart disease (CHD) in Pakistani patients...
  29. ncbi Drug treatment of combined hyperlipidemia
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Am J Cardiovasc Drugs 1:327-36. 2001
    ..Combined hyperlipidemia is likely to become an increasing problem with the increase in the prevalence of obesity and diabetes mellitus and needs aggressive management to reduce cardiovascular risk...
  30. ncbi Statins and hypertension
    A S Wierzbicki
    1St Thomas Hospital, London, UK
    J Hum Hypertens 20:554-6. 2006
  31. ncbi Cardiovascular risk factors and endothelial dysfunction
    Anthony S Wierzbicki
    Department of Chemical Pathology, King s College London King s, Guy s and St Thomas Medical School, St Thomas Hospital Campus, Lambeth Palace Road, London SE1 7EH, UK
    Clin Sci (Lond) 107:609-15. 2004
    ..The stronger relationship of endothelial dysfunction with PROCAM risk reflects the contribution of male sex, LDL-cholesterol and triacylglycerols to risk calculated by this algorithm...
  32. doi A fishy business: omega-3 fatty acids and cardiovascular disease
    A S Wierzbicki
    St Thomas Hospital, Lambeth Palace Road, London, UK
    Int J Clin Pract 62:1142-6. 2008
  33. ncbi Homocysteine and cardiovascular disease: a review of the evidence
    Anthony S Wierzbicki
    St Thomas Hospital, Lambeth Palace Road, London, UK
    Diab Vasc Dis Res 4:143-50. 2007
    ..Data from ongoing clinical trials are awaited to clarify this issue...
  34. ncbi Atorvastatin
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
    Expert Opin Pharmacother 2:819-30. 2001
    ..Other end point trials are in progress...
  35. ncbi Lipid-lowering drugs in lupus: an unexplored therapeutic intervention
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Lupus 10:233-6. 2001
    ..The role of lipid-lowering drugs in the management of both the acute and chronic sequelae of lupus needs to be explored...
  36. ncbi Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Am J Hypertens 14:32-7. 2001
    ..We conclude that VLDL triglyceride is strongly correlated with SLC maximal velocity and activity in patients with type V hyperlipidemia...
  37. ncbi Differing relationships of methylene tetrahydrofolate reductase genotypes with cardiovascular risk in familial and polygenic hypercholesterolaemia
    A S Wierzbicki
    Department of Chemical Pathology, King s College Guy s, King s and St Thomas Medical School, St Thomas Hospital Campus, London, UK
    J Cardiovasc Risk 7:431-4. 2000
    ..Plasma homocysteine and the methylene tetrahydrofolate reductase C677T polymorphism have been suggested as being risk factors for cardiovascular disease...
  38. ncbi High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia
    A S Wierzbicki
    Department of Chemical Pathology, King s College London, Guy s, King s and St Thomas Medical School, United Kingdom
    Am J Cardiol 86:547-9, A9. 2000
    ..Triglyceride reduction was only dependent on HDL:apolipoprotein A1, change in apolipoprotein B, and dose response, whereas an increase in HDL was dependent on initial LDL, change in LDL or dose response, and therapy with simvastatin...
  39. ncbi Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    J Hum Hypertens 14:561-5. 2000
    ..01). Cholesterol and triglyceride concentrations rather than insulin resistance seem to be the key features affecting the environmental alteration of sodium lithium countertransporter Vmax in patients with familial hypercholesterolaemia...
  40. ncbi Identification of genetic heterogeneity in Refsum's disease
    A S Wierzbicki
    Department of Chemical Pathology, King s Guy s and St Thomas Medical School, King College, London, UK
    Eur J Hum Genet 8:649-51. 2000
    ..This suggests that Refsum's disease, in common with other peroxisomal 'diseases', may be more accurately described as a heterogeneous syndrome...
  41. ncbi A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease
    A S Wierzbicki
    King s College, London, UK
    J Cardiovasc Risk 7:63-71. 2000
    ..To compare nine different algorithms for determining the necessity for drug treatment of hyperlipidaemia in patients without cardiovascular disease...
  42. ncbi Usefulness of Orlistat in the treatment of severe hypertriglyceridemia
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, United Kingdom
    Am J Cardiol 89:229-31. 2002
  43. ncbi Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    J Neurochem 80:727-35. 2002
    ....
  44. ncbi Beyond LDL-C--the importance of raising HDL-C
    Anthony S Wierzbicki
    Dept of Chemical Pathology, King s College London, Guy s, King s and St Thomas Medical School, UK
    Curr Med Res Opin 18:36-44. 2002
    ..New lipid-modifying drugs with beneficial effects on both HDL-C and LDL-C levels would be desirable additions to the currently available therapeutic options...
  45. doi Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia
    Anthony S Wierzbicki
    St Thomas Hospital, London, UK
    Curr Opin Cardiol 24:372-9. 2009
    ..New data have emerged over the last few years about the role of fibrates in treatment of microvascular and macrovascular disease...
  46. ncbi Future challenges for microsomal transport protein inhibitors
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London SE1 7EH, UK
    Curr Vasc Pharmacol 7:277-86. 2009
    ..Continuing attempts to utilise this clinical target (to decrease cholesterol, triglycerides and weight) have involved the use of lower doses or non systemically absorbed MTP inhibitors...
  47. doi Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, London SE1 7EH, UK
    Drug Saf 33:115-25. 2010
    ..At present, the most important need is for trials to be performed in children using accepted surrogate endpoints to define whether lipid-lowering drug therapy is beneficial in this group...
  48. doi Aortic stenosis and lipids: does intervention work?
    Anthony S Wierzbicki
    Guy s and St Thomas Hospitals, UK
    Curr Opin Cardiol 25:379-84. 2010
    ..Both histological and epidemiological studies have suggested that the process of valve degeneration may resemble atherosclerosis. This review investigates the potential role of lipid-lowering therapy in its management...
  49. doi Fibrates: no ACCORD on their use in the treatment of dyslipidaemia
    Anthony S Wierzbicki
    St Thomas Hospital, London, UK
    Curr Opin Lipidol 21:352-8. 2010
    ..New data have emerged over the last few years about the role of fibrates in treatment of microvascular and macrovascular disease...
  50. ncbi The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, United Kingdom
    Am J Hypertens 15:633-7. 2002
    ..The presence of apolipoprotein (apo) E variants is associated with hypertriglyceridemia. This study investigated the relationship between apoE phenotype and SLC kinetics...
  51. doi The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis
    Anthony S Wierzbicki
    Department of Cardiology, Conquest East Sussex Hospital, Hastings, UK
    Curr Med Res Opin 26:2141-6. 2010
    ..To investigate the long-term efficacy of fibrate-statin combination therapy on cardiovascular events as opposed to lipid levels...
  52. pmc Total research productivity in a pathology discipline
    A S Wierzbicki
    St Thomas s Hospital, Lambeth Palace Road, London SE1 7EH, UK
    J Clin Pathol 55:495-8. 2002
    ..To investigate the research productivity of all staff in chemical pathology...
  53. ncbi Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'Sweet Pee'
    Timothy C Hardman
    Consultant Chemical Pathologist St Thomas Hospital, Lambeth Palace Road London SE1 7EH UK
    Curr Pharm Des 16:3830-8. 2010
    ..Clinical development programs will need to establish those patients most likely to benefit from inhibition of SGLT2...
  54. ncbi Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease)
    A S Wierzbicki
    St Thomas Hospital, London, UK
    J Inherit Metab Dis 24:527-34. 2001
    ....
  55. ncbi Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter
    A S Wierzbicki
    St Thomas Hospital, London, UK
    Eur J Clin Invest 28:334-8. 1998
    ..Refsum's disease is characterized by progressive neurological dysfunction and accumulation of phytanic acid, an isoprenoid fatty acid, in fat-containing tissues...
  56. ncbi Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    QJM 92:387-94. 1999
    ..This issue needs further study in randomized controlled trials...
  57. ncbi Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia
    A S Wierzbicki
    Lipid Unit, Department of Chemical Pathology, King s College, London
    Hypertension 36:808-12. 2000
    ..06) and increased to 3.10 (95% CI, 1.20 to 7.52; P=0.04) after adjustment for other risk factors. The AG2R A1166C polymorphism may interact with severe hypercholesterolemia and other risk factors to increase risk of CHD in FH patients...
  58. ncbi Cardiovascular risk factors determine erectile and arterial function response to sildenafil
    Hemant Solomon
    Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, London, United Kingdom
    Am J Hypertens 19:915-9. 2006
    ..Sildenafil is effective in treatment of erectile dysfunction but shows variable results. This study investigated the relationship of cardiovascular risk factors to acute and chronic responses to sildenafil...
  59. ncbi Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study
    E R Christ
    Department of Medicine, St Thomas Hospital, London, United Kingdom
    J Clin Endocrinol Metab 84:307-16. 1999
    ....
  60. ncbi Erectile dysfunction and statin treatment in high cardiovascular risk patients
    H Solomon
    Department of Cardiology, Cardiothoracic Centre, St Thomas Hospital, Lambeth Palace Road, London, UK
    Int J Clin Pract 60:141-5. 2006
    ..This study suggests ED following statin therapy is more likely in patients with severe endothelial dysfunction due to established cardiovascular risk factors including age, smoking and diabetes...
  61. ncbi Transport of phytanic acid on lipoproteins in Refsum disease
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    J Inherit Metab Dis 22:29-36. 1999
    ..These ratios of apolipoprotein particles may play a significant role in determining the rate of phytanic acid elimination in patients with Refsum disease...
  62. ncbi Effect of moxonidine on lipid subfractions in patients with hypertension
    P J Lumb
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Int J Clin Pract 58:465-8. 2004
    ....
  63. ncbi Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia
    A S Wierzbicki
    Department of Chemical Pathology, King s College London, Guy s, King s and St Thomas Medical School, United Kingdom
    Am J Cardiol 87:338-40, A9. 2001
    ..Hyperfibrinogenemia was associated with atorvastatin, baseline fibrinogen, and initial concentration and change in concentration of apolipoprotein B or low-density lipoprotein cholesterol...
  64. doi Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD)
    P Manghat
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Bone 48:1127-32. 2011
    ..029). Our data suggest a link between imbalances in bone turnover and arterial stiffness in pre-dialysis CKD. Longitudinal studies are needed to evaluate the clinical usefulness of these bone turnover markers as predictors of CVD in CKD...
  65. ncbi Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease
    O Badawy
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Int J Clin Pract 57:249-51. 2003
    ..Combination therapy with low frequency (weekly) fibrate administration and daily statin treatment may provide a means to control the severe hypertriglyceridaemia of patients with renal disease...
  66. pmc Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study
    M Aboud
    HIV Medicine, Guy s and St Thomas Hospitals, London, UK
    Int J Clin Pract 64:1252-9. 2010
    ..The aim of this study is to determine the cardiovascular disease (CVD) risk profile of a large UK HIV cohort and how highly active antiretroviral therapy (HAART) affects this...
  67. ncbi Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas' Hospital, London, UK
    Int J Clin Pract 55:673-5. 2001
    ..One late case of rhabdomyolysis was observed, suggesting patients on the 120 mg dose require continued regular review...
  68. ncbi The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel
    D P Mikhailidis
    Dept Clinical Biochemistry Vascular Disease Prevention Clinics Royal Free Hospital, Royal Free and University College Medical School, London, UK
    Curr Med Res Opin 21:959-69. 2005
    ..The available evidence for ezetimibe is reviewed. The role of ezetimibe in increasing the proportion of patients attaining LDL-C treatment goals is discussed...
  69. ncbi Lipid lowering: another method of reducing blood pressure?
    A S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    J Hum Hypertens 16:753-60. 2002
    ....
  70. ncbi Erectile dysfunction: cardiovascular risk and the role of the cardiologist
    H Solomon
    Department of Cardiology, St Thomas Hospital, London, UK
    Int J Clin Pract 57:96-9. 2003
    ..ED is associated with a high incidence of occult cardiovascular disease. We suggest that cardiologists can significantly contribute to the management of ED...
  71. ncbi Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients
    Behdad Afzali
    Nephrology and Transplantation, Guy s Hospital, London, UK
    J Nephrol 16:540-5. 2003
    ..Thus sialic acid may be a superior marker to CRP for assessment of chronic inflammation in patients undergoing dialysis...
  72. ncbi Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, SE1 7EH, London, UK
    Int J Cardiol 84:53-7. 2002
    ..At higher doses, simvastatin increased HDL-C and Apo A-I significantly more than atorvastatin. These data indicate that statins may not be identical in all their clinical properties relevant to reducing the risks of atherosclerosis...
  73. pmc Smell testing: an additional tool for identification of adult Refsum's disease
    F B Gibberd
    Refsum s Disease Clinic, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Neurol Neurosurg Psychiatry 75:1334-6. 2004
    ..The diagnosis is confirmed by the presence of phytanic acidaemia. Although reduced smell function has been described in ARD, its value in the diagnosis of the condition has not been fully evaluated...
  74. ncbi Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus
    E R Christ
    Department of Medicine, King s College London, St Thomas s Hospital, UK
    Clin Endocrinol (Oxf) 55:777-87. 2001
    ..Secretion and clearance of VLDL apolipoprotein B100 (apoB) are important determinants of plasma lipid concentrations and are known to be influenced by hormones, including insulin and growth hormone...
  75. ncbi The lipid and non-lipid effects of statins
    Anthony S Wierzbicki
    Department of Chemical Pathology, GKT School of Medicine, King s College London, London, UK
    Pharmacol Ther 99:95-112. 2003
    ..The relative importance of the lipid- and non-lipid-related effects of the statins in the clinical situation remains the subject of much continuing research...
  76. ncbi Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial
    Theresa Marteau
    Psychology and Genetics Research Group, King s College London, London, United Kingdom
    Am J Med Genet A 128:285-93. 2004
    ..Further work is needed to determine whether similar results will be obtained in populations with little previous awareness of their risks...
  77. ncbi Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men
    Narbeh Melikian
    Cardiovascular Division, King s College London School of Medicine at Guy s, King s College and St Thomas Hospitals, London, United Kingdom
    Hypertension 49:873-7. 2007
    ..This may contribute to the lower NO bioavailability and higher incidence of cardiovascular disease seen in black Africans...
  78. doi Lipoprotein a: where are we now?
    Konstantinos Tziomalos
    Department of Clinical Biochemistry Vascular Prevention Clinic, Royal Free Hospital Campus, University College Medical School, University College London, London, UK
    Curr Opin Cardiol 24:351-7. 2009
    ..To provide an update of the literature describing the link between lipoprotein a and vascular disease...
  79. ncbi Statin therapy in people with diabetes and high-risk patients
    Anthony S Wierzbicki
    St Thomas Hospital, London SE1 7EH
    Hosp Med 64:16-9. 2003
    ..Primary prevention is dependent on identification and treatment of patients at high risk of which patients with diabetes are the clearest example. This article reviews the role of lipid lowering in high-risk individuals...
  80. ncbi Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation
    Rashed S Bakri
    Nephrology and Transplantation, Guy s Hospital, London, UK
    Clin Transplant 18:201-4. 2004
    ..Cardiovascular disease (CVD) is more common in patients with renal failure, even after renal transplantation. We wished to examine the relationship between markers of inflammation and CVD in stable renal transplant patients...
  81. ncbi Hypertriglyceridaemia and malignancy
    S Wijeratne
    St Thomas Hospital, London SE1 7EH, UK
    Int J Clin Pract 59:253-5. 2005
    ..These case reports illustrate that haematological and solid organ malignancies and autoimmunity may be relevant as exacerbating factors in the presentation of severe type IV or V hypertriglyceridaemia...
  82. ncbi Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women
    John Somner
    Department of Chemical Pathology, St Thomas Hospital, London, SE1 7EH United Kingdom
    J Clin Endocrinol Metab 89:344-51. 2004
    ..012). Subjects with the CC genotype had significantly lower BMD (mean +/- SD: TT, 0.7 +/- 0.16; CC, 0.6 +/- 0.08 g/cm(2); P = 0.006). In conclusion, both CYP 17 and CYP 19 are candidate genes for osteoporosis in postmenopausal women...
  83. doi The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease
    Eleanor J Baldwin
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    J Neurol Neurosurg Psychiatry 81:954-7. 2010
    ..To evaluate the long-term effectiveness of dietary therapy with regular dietetic reinforcement for adult Refsum disease...
  84. ncbi Dyslipidaemia and cardiovascular risk in HIV infection
    Ranjababu Kulasekaram
    HIV Medicine, St Thomas Hospital, London, UK
    Curr Med Res Opin 21:1717-25. 2005
    ....
  85. doi Factors regulating circulating vascular endothelial growth factor (VEGF): association with bone mineral density (BMD) in post-menopausal osteoporosis
    Nikola Costa
    Department of Chemical Pathology, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Cytokine 46:376-81. 2009
    ..017 and C(936)T: p=0.05. Circulating VEGF may be influenced by genetic, environmental and endocrine factors. Polymorphic variants in the VEGF gene are associated with spine BMD. Further larger studies are needed...
  86. doi HIV lipodystrophy and its metabolic consequences: implications for clinical practice
    Anthony S Wierzbicki
    Department of Chemical Pathology, St Thomas Hospital, London, UK
    Curr Med Res Opin 24:609-24. 2008
    ..As life expectancy has improved, the chronic complications of HIV and HAART have become increasingly relevant...
  87. ncbi Images in clinical medicine. Lipemia retinalis
    Jesse Kumar
    St Thomas Hospital, London SE1 7EH, United Kingdom
    N Engl J Med 353:823. 2005
  88. ncbi Dr Brian Gibberd (1931-2006): a pioneering clinician in Refsum's disease
    A S Wierzbicki
    Refsum s Disease Clinic, Chelsea and Westminster Hospital, London SW10 9NH, U K
    Biochem Soc Trans 35:862-4. 2007
    ..This work was presented as part of the Cardiovascular Bioscience focused topic at the Life Sciences 2007 conference, and this mini-symposium was dedicated to Dr Gibberd and his important contributions to this field...
  89. ncbi Hypertriglyceridaemia and NK cell lymphoma
    S Suryanarayanan
    St Thomas Hospital, London, UK
    Int J Clin Pract 57:921-2. 2003
    ..Lymphomas should be considered as part of the differential diagnosis in type IV-V hyperlipidaemia...
  90. ncbi The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E
    Paul Newman
    The Haemophilia Centre, St Thomas s Hospital, London, United Kingdom
    J Bone Miner Res 17:426-33. 2002
    ..The inhibition by heparin of lipoprotein-mediated carriage of vitamin K and possibly other lipids to bone may provide a basis for the future understanding of heparin-induced osteoporosis...
  91. ncbi Simple sequence-specific-primer-PCR method to identify the three main apolipoprotein E haplotypes
    Panagiotis Pantelidis
    Pan Pathology Molecular Diagnostics Laboratory, St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, UK
    Clin Chem 49:1945-8. 2003
  92. ncbi Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study
    Emanuel R Christ
    Department of Endocrinology and Diabetology, University Hospital of Bern, Switzerland
    Eur J Endocrinol 154:459-66. 2006
    ..The underlying mechanisms are not fully elucidated...
  93. ncbi Utilization of sterol carrier protein-2 by phytanoyl-CoA 2-hydroxylase in the peroxisomal alpha oxidation of phytanic acid
    Mridul Mukherji
    The Oxford Centre for Molecular Science, The Dyson Perrins Laboratory, South Parks Road, OX1 3QY, Oxford, United Kingdom
    Chem Biol 9:597-605. 2002
    ....
  94. ncbi Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing
    Steve E Humphries
    Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free and University College London Medical School, Rayne Building, 5 University Street, London WC1E 6JJ, UK
    J Mol Med (Berl) 84:203-14. 2006
    ..This supports the usefulness of DNA testing to confirm diagnosis of FH for the treatment of hyperlipidaemia and for further cascade screening...
  95. ncbi Cardiovascular risk assessment
    Anthony S Wierzbicki
    Lancet 365:1305-6. 2005
  96. ncbi Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis
    Sania Nishtar
    Heartfile, 1 Park Road, Chak Shahzad, Islamabad, Pakistan
    Curr Med Res Opin 20:55-62. 2004
    ..To establish risk factor causal associations for coronary artery disease (CAD) in the native Pakistani population...
  97. ncbi Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening
    Timothy M Reynolds
    Consultant Chemical Pathologist, Queen s Hospital, Burton on Trent and Division of Clinical Sciences, Wolverhampton University, UK
    Curr Med Res Opin 20:811-8. 2004
    ..The predictive capacities of 3 different risk identification systems based on computer calculation (the Framingham algorithm), or on tabular methods (the Sheffield tables and the General Rule to Enable Atheroma Treatment) were evaluated...
  98. ncbi A review of the lipid-related effects of fluvastatin
    Evagelos N Liberopoulos
    Department of Internal Medicine, Medical School, University of Ioannina, Greece
    Curr Med Res Opin 21:231-44. 2005
    ..This review considers the pharmacology, nonlipid-lowering effects and clinical trial evidence of fluvastatin based on a survey of PubMed entries...
  99. ncbi Letter regarding article by Gazzaruso et al, "Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated, type 2 diabetic patients"
    Graham Jackson
    Circulation 111:e18-9; author reply e18-9. 2005
  100. ncbi Clinical significance of oxidation from phytol to phytanic acid in man
    Anthony S Wierzbicki
    Mol Genet Metab 83:347. 2004
  101. ncbi Role of phytanoyl-CoA 2-hydroxylase in phytanic acid metabolism
    Matthew D Lloyd
    Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
    Adv Exp Med Biol 544:303-4. 2003